Interventional News recommends that readers watch Edward (Ted) Diethrich’s moving video that draws attention to the dangers of working with radiation. The video (below) follows the renowned American cardiovascular surgeon’s journey in which he discovers that he has a brain tumour. Simultaneously fact-filled and moving, the viewer is drawn into the story of the talented young surgeon with superb skills and training who was an early adopter of the endovascular approach, which meant that he was chronically exposed to ionising radiation, despite the use of protective gear.
The results of a research study indicate that interventional cardiologists receive “very high” radiation exposure levels to the left side of the head specifically when performing fluoroscopically guided invasive cardiovascular procedures.
A new European‐wide observational study to prospectively gather data on patients treated with irinotecan‐loaded microspheres has been launched by the Cardiovascular and Interventional Radiological Society of Europe (CIRSE). The CIRSE Registry for LifePearl microspheres (CIREL) will begin early in 2016.
Research published in the Journal of the American College of Radiology in June suggests that hospital costs to place a chest port were significantly lower in the interventional radiology suite than in the operating room. Patients who were treated by radiology and surgery did not show a significantly different rate of complications and/or infections.
Medtronic plc has announced that it has acquired Medina Medical, a Menlo Park, California, USA-based and privately-held medical device company focused on commercialising state-of-the-art treatments for vascular abnormalities of the brain including cerebral aneurysms.
Surefire, a developer of a new class of direct-to-tumour treatment delivery devices employed in minimally invasive chemoembolization and radioembolization procedures, announced that the company has received US510(k) FDA clearance for Precision. The infusion technology’s unique expandable tip increases drug delivery into the tumour while protecting healthy tissue.
Ramon Varcoe, Prince of Wales Hospital, Sydney, New South Wales, Australia and colleagues published the clinical and imaging outcomes obtained when they investigated a new bioresorbable vascular scaffold (Absorb, Abbott Vascular) for the treatment of focal tibial and distal popliteal lesions in the Journal of Endovascular Therapy (JEVT) in April 2015. They subsequently presented their first experience with the everolimus-eluting, bioresorbable scaffold for use in peripheral arteries below the knee at EUROPCR in Paris, France. The study was also published in EuroIntervention.
The first US commercial case using Silk Road Medical’s Enroute transcarotid stent system has been successfully performed at Kaiser Permanente Moanalua Medical Center in Honolulu, Hawaii, by vascular surgeon Peter A Schneider. The Enroute transcarotid stent is designed specifically for transcarotid artery revascularisation (TCAR), combining the surgical principles of neuroprotection with minimally invasive endovascular techniques to treat blockages in the carotid artery at risk of causing a stroke.
InspireMD announced the full market launch of the CGuard Embolic Prevention System for the treatment of carotid artery disease by its strategic distribution partner, Penumbra, at the CIRSE Annual Congress (26–30 September, Lisbon, Portugal). Penumbra leverages its direct European commercialisation team to launch CGuard distributed by Penumbra.
Gerard O’Sullivan announced preliminary results from a European study of venous stents at the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) 2015 meeting (26–30 September, Lisbon, Portugal). O’Sullivan is the principal investigator of the VIVO-EU study at the University Hospital Galway, Ireland.
The trial’s results were published in JACC: Cardiovascular Interventions and show no intracranial haemorrhage and no death among massive pulmonary embolism patients.
Medtronic has announced favourable five-year data in the VALOR II study, demonstrating the durability of the Valiant thoracic stent graft system, an innovative and minimally invasive treatment for patients with thoracic aortic aneurysms (TAA).
The first US commercial case using Silk Road Medical’s Enroute transcarotid stent system has been successfully performed at Kaiser Permanente Moanalua Medical Center in Honolulu, Hawaii, by vascular surgeon Peter A Schneider. The Enroute transcarotid stent is designed specifically for transcarotid artery revascularisation (TCAR), combining the surgical principles of neuroprotection with minimally invasive endovascular techniques to treat blockages in the carotid artery at risk of causing a stroke.
The US Food and Drug Administration has granted conditional approval for a US and European Investigational Device Exemption (IDE) clinical trial to investigate the use of the Intact Vascular’s Tack Endovascular System as a dissection repair therapy in patients with peripheral arterial disease undergoing percutaneous angioplasty.
Researchers at Queen Mary University of London (QMUL) have developed a way of assembling organic molecules into complex tubular tissue-like structures without the use of moulds or techniques like 3D printing.
Cookies Sociales
Son esos botones que permiten compartir el contenido del sitio web en sus redes sociales (Facebook, Twitter y Linkedin, previo tu consentimiento y login) a través de sistemas totalmente gestionados por dichas redes sociales, así como los recursos (pej. videos) y material que se encuentra en nuestra web, y que de igual manera se presta y gestiona completamente por un tercero.
Si no acepta estas cookies, no podrá compartir nuestro contenido a través de los botones, y en su caso, no podrás visualizar el contenido de terceros que hayamos incrustado en el sitio.
No las utilizamos